A study to compare zoledronic acid and calcium and vitamin D, with placebo (dummy) and calcium and vitamin D, on the frequency of hip fractures and of new spinal fractures in postmenopausal women with osteoporosis

Recruitment status No longer recruiting	Prospectively registered	
	☐ Protocol	
Overall study status Completed	Statistical analysis plan	
	[X] Results	
Condition category Musculoskeletal Diseases	Individual participant data	
	No longer recruiting Overall study status Completed Condition category	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr R Eastell

Contact details

Metabolic Bone Centre Sorby Wing Northern General Hospital Herries Road Sheffield United Kingdom S5 7AU +44 0114 2714705 r.eastell@sheffield.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00049829

Secondary identifying numbers

N0059115932

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

For the UK part of the trial, approved by North Sheffield Research Ethics Committee, reference NS02 1 1247, date of favourable opinion 21/03/02.

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Musculoskeletal Diseases: Osteoporosis

Interventions

Compare zoledronic acid and calcium and vitamin D, with placebo (dummy) and calcium and vitamin D.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Zoledronic acid, calcium, vitamin D

Primary outcome measure

Added 31 July 2008:

- 1. To assess the incidence of hip fractures in all patients treated with zoledronic acid compared to patients in the placebo group at 3 years
- 2. To assess the incidence of new vertebal fractures in patients treated with zolendronate acid compared to patients taking placebo at 3 years among patients not taking concomitant therapy for osteoporosis at baseline (stratum 1)

Secondary outcome measures

Added 31 July 2008:

- 1. Percent change in hip BMD as measured by DXA over 3 years
- 2. Proportion of patients in stratum 1 with new and/or worsening vertebral fractures at 1 year
- 3. Incidence of all clinical fractures in stratum 1 and 2 over 3 years

Overall study start date

01/07/2002

Completion date

30/06/2003

Eligibility

Key inclusion criteria

Post-menopausal women with osteoporosis.

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

7,400 worldwide

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/07/2002

Date of final enrolment

Locations

Countries of recruitment

England

Germany

United Kingdom

United States of America

Study participating centre Metabolic Bone Centre Sheffield United Kingdom S5 7AU

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.doh.gov.uk

Funder(s)

Funder type

Industry

Funder Name

Sheffield Teaching Hospitals (UK)

Funder Name

Novartis

Alternative Name(s)

Novartis AG, Novartis International AG

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

Switzerland

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	03/05/2007		Yes	No